Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo.
暂无分享,去创建一个
Leonard Moise | Anne S De Groot | Chang Song | David W Scott | D. Scott | A. D. De Groot | Chang Song | W. Martin | William D Martin | L. Moise | Ryan Tassone | Ryan Tassone
[1] D. Scott,et al. De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain , 2008 .
[2] Anne S. De Groot,et al. Immunomics: discovering new targets for vaccines and therapeutics , 2006 .
[3] P. Lenting,et al. The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.
[4] J. Healey,et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. , 1998, Blood.
[5] W. Martin,et al. De-immunization of therapeutic proteins by T-cell epitope modification. , 2005, Developments in biologicals.
[6] J. Lusher,et al. The safety and efficacy of B‐domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[7] W. Ouwehand,et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. , 2000, Blood.
[8] M. Ragni,et al. Disappearance of inhibitor to factor VIII in HIV‐infected hemophiliacs with progression to AIDS or severe ARC , 1989, Transfusion.
[9] D. Scott,et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.
[10] J Bayry,et al. Pathophysiology of inhibitors to factor VIII in patients with haemophilia A , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.
[11] D. Scott,et al. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. , 2005, Blood.
[12] William W. Kwok,et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.
[13] W. Kreuz,et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.
[14] J. Goedert,et al. Loss of high‐responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi‐center hemophilia cohort study , 1993, American journal of hematology.
[15] A. D. De Groot,et al. An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. , 1997, AIDS research and human retroviruses.
[16] J. Healey,et al. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. , 2000, Blood.
[17] C. Kessler,et al. The safety and efficacy of B‐domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A , 2003 .
[18] P. Fay,et al. Human Inhibitor Antibodies Specific for the Factor VIII A2 Domain Disrupt the Interaction between the Subunit and Factor IXa* , 1999, The Journal of Biological Chemistry.
[19] P. Fay,et al. Localization of Factor IXa and Factor VIIIa Interactive Sites (*) , 1995, The Journal of Biological Chemistry.
[20] Jeffrey A. Ledbetter,et al. How B and T cells talk to each other , 1994, Nature.
[21] B. Dahlbäck,et al. Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients. , 1990, Blood.
[22] J. Vermylen,et al. CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A. , 2003, Blood.
[23] I. Maclennan,et al. Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl‐2 induction , 1993, European journal of immunology.
[24] Leonard Moise,et al. Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.
[25] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[26] T. Ortel,et al. Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. , 2002, Blood.
[27] D. Scott,et al. A role for thrombin in the initiation of the immune response to therapeutic factor VIII. , 2009, Blood.
[28] A. D. De Groot,et al. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.
[29] M F Hoylaerts,et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. , 1998, Blood.
[30] J. Oldenburg,et al. Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome , 1999, Vox Sanguinis.
[31] E. Gordon,et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. , 1994, Blood.
[32] Moses Rodriguez,et al. A New Humanized HLA Transgenic Mouse Model of Multiple Sclerosis Expressing Class II on Mouse CD4 T Cells , 2007, Annals of the New York Academy of Sciences.
[33] J. Oldenburg,et al. Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products. , 2002, Seminars in thrombosis and hemostasis.
[34] Anne S De Groot,et al. Immunomics: discovering new targets for vaccines and therapeutics. , 2006, Drug discovery today.
[35] C. David,et al. Characterization of HLA DR2 and DQ8 transgenic mouse with a new engineered mouse class II deletion, which lacks all endogenous class II genes. , 2003, Journal of autoimmunity.
[36] S. Arkin,et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.
[37] D. Scott,et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site , 2004, Thrombosis and Haemostasis.
[38] E. Lam,et al. CD40: a pivotal receptor in the determination of life/death decisions in B lymphocytes. , 1997, International reviews of immunology.
[39] D. Okita,et al. Epitope repertoire of human CD4+ T cells on the A3 domain of coagulation factor VIII , 2004, Journal of thrombosis and haemostasis : JTH.
[40] N. Key,et al. Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in Congenital and Acquired Hemophilia Patients and in Healthy Subjects , 2000, Thrombosis and Haemostasis.
[41] S. Lacroix-Desmazes,et al. Inhibitors in haemophilia: pathophysiology , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[42] S. Ziegler,et al. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. , 2009, Blood.
[43] Marc De Maeyer,et al. Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.
[44] D. Okita,et al. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects , 2004, Journal of thrombosis and haemostasis : JTH.
[45] K. Koshibu,et al. The A1 and A2 Subunits of Factor VIIIa Synergistically Stimulate Factor IXa Catalytic Activity* , 1999, The Journal of Biological Chemistry.
[46] G. E. Gilbert,et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. , 1995, Blood.
[47] L. Burkly,et al. Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer , 2000, European journal of immunology.
[48] S. Antonarakis,et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A , 1995, Nature Genetics.
[49] Sylvie Villard,et al. Anti-factor VIII antibodies , 2005, Thrombosis and Haemostasis.
[50] A. Sharpe,et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .
[51] B. Sack,et al. Induction of tolerance to factor VIII by transient co‐administration with rapamycin , 2011, Journal of thrombosis and haemostasis : JTH.
[52] D. Okita,et al. Human CD4+ T‐cell epitope repertoire on the C2 domain of coagulation factor VIII , 2003, Journal of thrombosis and haemostasis : JTH.
[53] H. Schwarz,et al. Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune Tolerance , 2001, Thrombosis and Haemostasis.